Chinese herbal medicine Shufeng Jiedu capsule for mild to moderate COVID-19: a multicenter, randomized, double-blind, placebo-controlled phase II trial
Background: The COVID-19 pandemic has had a profound global impact, although the majority of recently infected cases have presented with mild to moderate symptoms. Previous clinical studies have demonstrated that Shufeng Jiedu (SFJD) capsule, a Chinese herbal patent medicine, effectively alleviates...
Saved in:
Main Authors: | Chun-li Lu (Author), Liu-qing Yang (Author), Xin-yan Jin (Author), Thomas Friedemann (Author), Yu-fei Li (Author), Xue-han Liu (Author), Xiao-ying Chen (Author), Xiang-yun Zou (Author), Bing-rui Zhang (Author), Fu-xiang Wang (Author), Yuan-long Lin (Author), Yi-min Tang (Author), Meng-li Cao (Author), Ya-lin Jiang (Author), You-fang Gao (Author), Kui Liu (Author), Zhen-gang Tao (Author), Nicola Robinson (Author), Sven Schröder (Author), Jian-ping Liu (Author), Hong-zhou Lu (Author) |
---|---|
Format: | Book |
Published: |
Frontiers Media S.A.,
2024-05-01T00:00:00Z.
|
Subjects: | |
Online Access: | Connect to this object online. |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Study on basic and clinical application of Shufeng Jiedu Capsule in treating respiratory tract infection
by: Yanqi Han, et al.
Published: (2023) -
Shufeng Jiedu capsules for treating acute exacerbations of chronic obstructive pulmonary disease: a systematic review and meta-analysis
by: Ru-yu Xia, et al.
Published: (2020) -
Chinese Patent Medicine Shufeng Jiedu Capsules as an Adjuvant Therapy for Community-Acquired Pneumonia: A Systematic Review and Meta-Analysis of Randomized Clinical Trials
by: Xiao-Wen Zhang, et al.
Published: (2022) -
A synthesis of the evidence regarding safety of a Chinese herbal formula Shufeng Jiedu: A pharmacological review
by: Jeanne Trill, et al.
Published: (2022) -
Huanglian Jiedu Decoction ameliorates DSS-induced colitis in mice via the JAK2/STAT3 signalling pathway
by: Zhuo Lu, et al.
Published: (2020)